GO:0006526 L-arginine biosynthetic process: Pathway, Genes, Functions and Research Methods
Research-grade guide for scientists and biopharma professionals
Key Takeaways
• GO:0006526 (L-arginine biosynthetic process) describes the chemical reactions and pathways that build arginine, a proteinogenic amino acid and precursor of nitric oxide, polyamines, creatine and urea cycle intermediates.
• Arginine biosynthesis is a metabolic node that intersects nitrogen disposal, immune cell function and vascular signaling, making it a frequent target in cancer and metabolic disease research.
• L-arginine availability modulates T cell metabolism, survival and anti-tumor activity, linking this biosynthetic process directly to immuno-oncology.
• Dysregulated arginine metabolism is implicated in diabetic cardiomyopathy, hypoxia-associated clinical conditions and obesity-related glucose and lipid dysfunction.
• Excess L-arginine can perturb MEK-ERK-NO signaling, as shown in experimental myopia models, illustrating that flux through this pathway must be tightly controlled.
• CRISPR knockout, point-mutation, knock-in and overexpression models enable causal dissection of genes annotated to GO:0006526 in human cells and animal models.
Description
GO:0006526, L-arginine biosynthetic process, is the biological process ontology term for the chemical reactions and pathways resulting in the formation of arginine, 2-amino-5-(carbamimidamido)pentanoic acid. Arginine is a conditionally essential amino acid that serves as a building block for proteins and as a substrate for nitric oxide synthases, arginases and other enzymes that generate signaling molecules. Because arginine sits at the intersection of nitrogen metabolism, vascular tone and immune regulation, the pathways that produce it are of broad interest to cell biologists, immunologists and metabolic disease researchers. The process is not merely a housekeeping route for amino acid supply. L-arginine availability modulates T cell metabolism and enhances survival and anti-tumor activity, indicating that biosynthetic flux can shape immune responses. In tumors, the metabolic pathways of L-arginine have therapeutic consequences, and manipulating arginine supply or catabolism is an active area of drug development. In diabetes and obesity, L-arginine modulates glucose and lipid metabolism, and its interaction with tetrahydrobiopterin and nitric oxide is relevant to endothelial function. For researchers, GO:0006526 provides a controlled vocabulary anchor for annotating genes, interpreting omics data and designing experiments. Studies of hypoxia, diabetic cardiomyopathy and even myopia have implicated L-arginine handling in disease mechanisms, underscoring the need for precise genetic models. This article summarizes the definition, core reactions, key genes, regulation, disease links and research methods relevant to GO:0006526, with all factual claims tied to verified PubMed references.
L-arginine biosynthetic process At A Glance
| GO ID | GO:0006526 |
|---|---|
| GO term | L-arginine biosynthetic process |
| Ontology | biological_process |
| Synonym | arginine anabolism; arginine biosynthesis; arginine formation; arginine synthesis |
| Definition | The chemical reactions and pathways resulting in the formation of arginine, 2-amino-5-(carbamimidamido)pentanoic acid. |
| Major function | Production of L-arginine for protein synthesis and as a precursor for nitric oxide, polyamines, creatine and urea cycle intermediates |
| Related metabolites | L-arginine, L-citrulline, L-ornithine, L-glutamate, L-glutamine, aspartate, fumarate |
| Related pathways | Urea cycle, nitric oxide signaling, polyamine biosynthesis, amino acid metabolism |
| Disease relevance | Cancer immunometabolism, diabetic cardiomyopathy, hypoxia, obesity and diabetes, myopia models |
What Is GO:0006526?
In the Gene Ontology, GO:0006526 (L-arginine biosynthetic process) is defined as the chemical reactions and pathways resulting in the formation of arginine, 2-amino-5-(carbamimidamido)pentanoic acid. It is a biological_process term with synonyms including arginine anabolism, arginine biosynthesis, arginine formation and arginine synthesis. The term covers enzymatic steps that convert precursors such as glutamate, glutamine, citrulline or ornithine into L-arginine, as well as the regulatory and cofactor-dependent reactions that support this conversion. It is distinct from arginine catabolism and from transport processes, although the products of biosynthesis feed into nitric oxide, polyamine and urea cycle pathways.
Why Is L-arginine biosynthetic process Important in Cell Biology?
GO:0006526 is important because L-arginine is not only a protein building block but also a central metabolic hub. Its biosynthesis supplies substrate for nitric oxide production, polyamine synthesis and the urea cycle, thereby influencing vascular tone, cell proliferation and nitrogen disposal. In immunology, L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity, so changes in biosynthetic capacity can alter immune surveillance. In metabolic disease, L-arginine availability interacts with glucose and lipid metabolism, and with tetrahydrobiopterin and nitric oxide in diabetes. In hypoxia-associated conditions, L-arginine has been evaluated for clinical benefit, reflecting its role in oxygen-dependent signaling. Consequently, genes annotated to this process are candidate targets for therapeutic modulation and for mechanistic studies using CRISPR models.
• Supplies L-arginine for protein synthesis and for precursors of nitric oxide, polyamines and creatine.
• Modulates T cell metabolism, survival and anti-tumor activity, linking metabolism to immunity.
• Interacts with glucose and lipid metabolism in obesity and diabetes.
• Connects to nitric oxide and tetrahydrobiopterin biology in diabetes and endothelial function.
• Relevant to diabetic cardiomyopathy as a multifaceted regulator.
• Studied in clinical conditions associated with hypoxia.
• Metabolic pathways of L-arginine have therapeutic consequences in tumors.
• Excess L-arginine can perturb MEK-ERK-NO signaling in experimental myopia.
• Provides a controlled vocabulary for omics annotation and pathway enrichment.
• Enables causal testing of metabolic genes via CRISPR knockout, knock-in and overexpression models.
What Happens During L-arginine biosynthetic process?
Precursor supply and nitrogen input
In simple terms: The cell first gathers the raw materials it needs to build arginine.
L-arginine biosynthesis depends on the availability of nitrogen-rich precursors such as glutamate, glutamine and aspartate, which feed into the pathway at different points. In tumors and immune cells, the metabolic pathways of L-arginine are closely tied to the supply of these precursors and to the activity of enzymes that interconvert them. The process is therefore sensitive to nutrient status and to the expression of amino acid transporters and transaminases that maintain precursor pools.
Conversion of citrulline and ornithine to arginine
In simple terms: Enzymes convert intermediate molecules like citrulline and ornithine into arginine.
A central route to L-arginine proceeds through citrulline and ornithine, with enzymes such as argininosuccinate synthase and argininosuccinate lyase catalyzing the final steps. These reactions are part of the broader urea cycle and amino acid metabolism network, and their flux can be modulated by substrate availability and by hormonal signals. In immune cells, the ability to generate L-arginine from these intermediates supports survival and effector function.
Cofactor-dependent reactions and nitric oxide coupling
In simple terms: Some steps need helper molecules, and the product arginine can be used to make nitric oxide.
L-arginine biosynthesis intersects with nitric oxide production, which requires tetrahydrobiopterin as a cofactor. In diabetes, altered L-arginine, tetrahydrobiopterin and nitric oxide balance contributes to endothelial dysfunction. This coupling means that biosynthetic flux can influence redox and signaling outcomes beyond simple amino acid supply.
Regulation by metabolic and hormonal signals
In simple terms: The pathway speeds up or slows down depending on the cell's metabolic state.
L-arginine modulates glucose and lipid metabolism in obesity and diabetes, indicating that biosynthetic and catabolic fluxes are integrated with systemic metabolic signals. In hypoxia-associated conditions, L-arginine availability may affect oxygen-dependent processes, and clinical studies have evaluated L-arginine in such settings. These observations support the view that GO:0006526 is a regulated process rather than a constitutive housekeeping route.
Downstream use of newly synthesized arginine
In simple terms: Once made, arginine is used for many jobs, including immune and vascular functions.
Newly synthesized L-arginine can be incorporated into proteins or converted into nitric oxide, polyamines and other metabolites. In T cells, L-arginine availability enhances survival and anti-tumor activity, showing that downstream use is functionally important. In tumors, the metabolic pathways of L-arginine have therapeutic consequences, and targeting these routes is an active research area.
Key Genes Involved in GO:0006526 L-arginine biosynthetic process
The following genes and proteins are functionally associated with L-arginine biosynthesis and its downstream use, based on published literature on arginine metabolism, immunity and metabolic disease.
| Gene | Major Role | Research Relevance |
|---|---|---|
| ASS1 | Argininosuccinate synthase, catalyzes a key step in arginine biosynthesis | Metabolic flux control and tumor metabolism |
| ASL | Argininosuccinate lyase, catalyzes the final step in arginine biosynthesis | Urea cycle and arginine supply |
| OTC | Ornithine transcarbamylase, part of the urea cycle and arginine precursor supply | Nitrogen disposal and metabolic disease |
| CPS1 | Carbamoyl phosphate synthetase 1, feeds nitrogen into the urea cycle | Hepatic metabolism and arginine precursor supply |
| ARG1 | Arginase 1, catabolizes arginine and regulates its availability | Immune suppression and tumor microenvironment |
| ARG2 | Arginase 2, mitochondrial arginase affecting arginine pools | Metabolic and vascular biology |
| NOS1 | Neuronal nitric oxide synthase, uses arginine to make nitric oxide | Signaling and hypoxia-related studies |
| NOS2 | Inducible nitric oxide synthase, consumes arginine in inflammation | Immune and inflammatory research |
| NOS3 | Endothelial nitric oxide synthase, uses arginine for vascular nitric oxide | Diabetes and endothelial function |
| GLS | Glutaminase, supplies glutamate for arginine precursor pools | Tumor and immune metabolism |
| GLUL | Glutamine synthetase, contributes to glutamine and glutamate balance | Metabolic flux studies |
| GOT1 | Aspartate aminotransferase, supports nitrogen transfer for arginine synthesis | Amino acid metabolism research |
| GOT2 | Mitochondrial aspartate aminotransferase, links TCA cycle and arginine precursors | Metabolic disease models |
| SLC7A1 | Cationic amino acid transporter, imports arginine and related amino acids | Arginine availability studies |
| SLC7A2 | Cationic amino acid transporter, affects arginine uptake | Immune and metabolic research |
| SLC3A2 | Amino acid transporter subunit, supports arginine transport | T cell metabolism and cancer |
| DDIT3 | Stress-responsive transcription factor linked to amino acid stress | Integrated stress response studies |
| HIF1A | Hypoxia-inducible factor, coordinates metabolic adaptation | Hypoxia and arginine metabolism |
How Is L-arginine biosynthetic process Regulated?
L-arginine biosynthesis is regulated at multiple levels. Substrate availability and enzyme expression control flux through the pathway, and hormonal and metabolic signals integrate this process with systemic glucose and lipid metabolism. In immune cells, L-arginine availability modulates T cell metabolism and survival, indicating that nutrient-sensing pathways influence the biosynthetic route. Nitric oxide production from arginine requires tetrahydrobiopterin, and imbalances in this coupling are relevant to diabetes. In hypoxia, L-arginine has been evaluated for clinical benefit, suggesting oxygen-dependent regulation. Together, these findings show that GO:0006526 is embedded in a regulatory network responsive to nutrients, oxygen and immune signals.
L-arginine biosynthetic process and Human Disease
| Gene | Disease / Biology | Potential Experimental Model |
|---|---|---|
| ASS1 | Tumor metabolism and arginine auxotrophy | Knockout in cancer cell lines followed by metabolomics |
| ASL | Urea cycle and arginine supply | Point-mutation knock-in in hepatocyte models |
| ARG1 | Immune suppression in tumor microenvironment | Overexpression in myeloid cells and co-culture with T cells |
| NOS3 | Diabetes and endothelial dysfunction | Knock-in of tagged NOS3 for imaging nitric oxide coupling |
| HIF1A | Hypoxia-associated metabolic adaptation | Knockout in hypoxia-exposed cells and arginine flux assays |
Cancer and tumor immunometabolism
L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity, linking arginine biosynthesis and availability to cancer immunity. Metabolic pathways of L-arginine have therapeutic consequences in tumors, and enzymes such as ARG1 and NOS2 can deplete arginine in the tumor microenvironment, affecting immune responses. These findings make genes in GO:0006526 candidate targets for immuno-oncology research.
Diabetes, obesity and cardiovascular disease
L-arginine modulates glucose and lipid metabolism in obesity and diabetes, and its interaction with tetrahydrobiopterin and nitric oxide is relevant to endothelial function. Diabetic cardiomyopathy is influenced by L-arginine as a multifaceted regulator, suggesting that biosynthetic flux and catabolism contribute to cardiac complications. These connections support research into arginine-handling genes as modifiers of metabolic and cardiovascular phenotypes.
Hypoxia-associated conditions
The effectiveness of L-arginine has been studied in clinical conditions associated with hypoxia, where oxygen-dependent nitric oxide production and vascular function are impaired. Because arginine is a substrate for nitric oxide synthases, changes in its biosynthesis or availability may influence adaptation to low oxygen. This provides a rationale for investigating GO:0006526 genes in hypoxia models.
Ocular and signaling disorders
Excessive L-arginine supplementation induced myopia in an experimental model via the MEK-ERK-NO signaling pathway, showing that excess arginine can perturb signaling. This finding highlights the need to understand how biosynthetic flux is controlled and how it intersects with kinase signaling. It also suggests that arginine-related genes may be relevant to ocular growth and refractive error research.
From L-arginine biosynthetic process-Related Genes to Experimental Models
| Research Question | Suitable Model |
|---|---|
| Does loss of a candidate gene reduce L-arginine biosynthesis? | CRISPR knockout cell line with metabolomics |
| Does a specific amino acid substitution alter enzyme activity? | Point-mutation knock-in via CRISPR |
| Can a reporter track pathway flux in live cells? | Tagged knock-in of pathway enzyme |
| Does overexpression of a transporter increase arginine availability? | Overexpression cell model |
| Which genes are essential in immune cells? | CRISPR library screening in T cells |
| How does hypoxia alter arginine metabolism? | Knockout plus hypoxia exposure and nitric oxide measurement |
How to Study the L-arginine biosynthetic process Process
| Method | What It Measures | Typical Application |
|---|---|---|
| LC-MS metabolomics | Levels of arginine, citrulline, ornithine | Pathway flux in knockout cells |
| Stable isotope tracing | Carbon and nitrogen flow through pathway | Mechanistic metabolism studies |
| RNA-seq | Expression of pathway genes | Disease model profiling |
| CRISPR library screening | Gene essentiality and fitness | Immune cell and cancer screens |
| Nitric oxide assay | Nitric oxide production from arginine | Endothelial and hypoxia studies |
| Western blot | Protein levels of pathway enzymes | Validation of knockout or overexpression |
| Immunofluorescence | Subcellular localization of enzymes | Mitochondrial and cytosolic pathway studies |
| Co-culture assays | T cell survival and anti-tumor activity | Immunometabolism research |
Metabolomics and flux analysis
Mass spectrometry-based metabolomics can quantify L-arginine and its precursors such as citrulline and ornithine, providing direct readouts of GO:0006526 activity. Stable isotope tracing can reveal how nitrogen and carbon flow through the pathway in cancer and immune cells. These methods are essential for validating CRISPR models of arginine metabolism.
Transcriptomics and pathway enrichment
RNA-seq and pathway enrichment analysis can identify genes annotated to GO:0006526 that are differentially expressed in disease models. In diabetes and obesity studies, expression changes in arginine-metabolizing genes correlate with metabolic phenotypes. Combining transcriptomics with metabolomics strengthens causal inference.
Nitric oxide and signaling assays
Because arginine is a substrate for nitric oxide synthases, measuring nitric oxide or its metabolites can report on pathway output. In myopia models, MEK-ERK-NO signaling was assessed after excess L-arginine, illustrating how signaling assays complement metabolic measurements. Such assays are useful in hypoxia and cardiovascular research.
CRISPR screening and functional genomics
Pooled CRISPR screens can test which genes in or related to GO:0006526 are required for cell survival or immune function. In T cells, L-arginine availability affects survival and anti-tumor activity, making screens in this context informative. Hits can then be validated with single-gene knockout and metabolomics.
How CRISPR Can Be Used to Study GO:0006526 L-arginine biosynthetic process
Knockout
CRISPR knockout of genes such as ASS1 or ASL can reduce L-arginine biosynthesis and reveal metabolic dependencies in cancer and immune cells. Knockout models combined with metabolomics provide direct causal evidence for pathway function. These models are also useful for testing compensatory routes of arginine supply.
Point Mutation
Point-mutation knock-in can model specific amino acid substitutions in enzymes of L-arginine biosynthesis, allowing structure-function studies. Such models help distinguish loss-of-function from altered-activity alleles in metabolic disease research. They are particularly valuable when complete knockout is lethal or confounded by compensation.
Knock-in
Tagged knock-in of pathway enzymes enables live-cell imaging and proteomic tracking of L-arginine biosynthetic machinery. Reporter knock-in can measure pathway activity in response to nutrients or hypoxia. These models support precise dissection of GO:0006526 regulation.
Overexpression
Overexpression of transporters or enzymes can increase L-arginine availability and test downstream effects on T cell function or nitric oxide production. In myopia models, excess L-arginine perturbed MEK-ERK-NO signaling, showing that overexpression studies can reveal signaling consequences. Overexpression models complement knockout approaches for bidirectional pathway control.
How EDITGENE Supports L-arginine biosynthetic process Research
Researchers studying L-arginine biosynthetic process-related genes often need to determine whether a candidate gene is causally involved in pathway flux, immune function or metabolic disease. EDITGENE provides CRISPR-based cell model services that enable knockout, point-mutation, knock-in and overexpression studies, as well as library screening and bioinformatics support, to accelerate hypothesis testing in this metabolic area.
Contact EDITGENE today to design your custom CRISPR model for L-arginine biosynthetic process research.
Related Products
| Product name | Cat.No. | Species | Gene ID | |
|---|---|---|---|---|
| ASL Knockout HEK293 Cell Line | EDJ-KQ3432 | Human | 435 | Details Get a Quote |
| ASS1 Knockout HEK293 Cell Line | EDJ-KQ4105 | Human | 445 | Details Get a Quote |
| OTC Knockout HEK293 Cell Line | EDJ-KQ5388 | Human | 5009 | Details Get a Quote |
| NAGS Knockout HEK293 Cell Line | EDJ-KQ14366 | Human | 162417 | Details Get a Quote |
| ASS1 Knockout HCT 116 Cell Line | EDJ-KQ25163 | Human | 445 | Details Get a Quote |
| NAGS Knockout HCT 116 Cell Line | EDJ-KQ44503 | Human | 162417 | Details Get a Quote |
| NAGS Knockout HeLa Cell Line | EDJ-KQ44504 | Human | 162417 | Details Get a Quote |
| ASL Knockout A-549 Cell Line | EDJ-KQ26490 | Human | 435 | Details Get a Quote |
| ASL Knockout HCT 116 Cell Line | EDJ-KQ26492 | Human | 435 | Details Get a Quote |
| ASL Knockout HeLa Cell Line | EDJ-KQ26493 | Human | 435 | Details Get a Quote |
| ASS1 Knockout A-549 Cell Line | EDJ-KQ26497 | Human | 445 | Details Get a Quote |
| ASS1 Knockout HeLa Cell Line | EDJ-KQ26499 | Human | 445 | Details Get a Quote |
| OTC Knockout HeLa Cell Line | EDJ-KQ54061 | Human | 5009 | Details Get a Quote |
| OTC Knockout A-549 Cell Line | EDJ-KQ62549 | Human | 5009 | Details Get a Quote |
| NAGS Knockout A-549 Cell Line | EDJ-KQ67324 | Human | 162417 | Details Get a Quote |
Displaying Records 1 To 15 Of 16 Records
Frequently Asked Questions About L-arginine biosynthetic process
What is GO:0006526 L-arginine biosynthetic process?
GO:0006526 is a Gene Ontology biological_process term defined as the chemical reactions and pathways resulting in the formation of arginine, 2-amino-5-(carbamimidamido)pentanoic acid.
What genes are involved in L-arginine biosynthetic process?
Genes such as ASS1, ASL, OTC and CPS1 contribute to arginine biosynthesis and precursor supply, while ARG1, ARG2 and NOS enzymes influence arginine availability and downstream use.
Why is L-arginine important for T cells?
L-arginine modulates T cell metabolism and enhances survival and anti-tumor activity, linking this pathway to immune function.
How is L-arginine related to nitric oxide?
L-arginine is the substrate for nitric oxide synthases, and this coupling requires tetrahydrobiopterin and is relevant to diabetes and endothelial function.
Is L-arginine involved in diabetes and obesity?
Yes, L-arginine modulates glucose and lipid metabolism in obesity and diabetes, and interacts with nitric oxide pathways.
Can excess L-arginine cause disease?
In an experimental model, excessive L-arginine supplementation induced myopia via MEK-ERK-NO signaling, showing that excess can perturb signaling.
What research methods are used to study L-arginine biosynthesis?
Metabolomics, stable isotope tracing, RNA-seq, CRISPR screening and nitric oxide assays are commonly used.
How can CRISPR help study GO:0006526?
CRISPR knockout, point-mutation, knock-in and overexpression models allow causal testing of genes involved in arginine biosynthesis and downstream effects.
What diseases are linked to L-arginine metabolism?
Cancer immunometabolism, diabetic cardiomyopathy, hypoxia-associated conditions and metabolic disorders have been linked to L-arginine metabolism.
Where can I get CRISPR cell models for arginine pathway genes?
EDITGENE provides knockout, point-mutation, knock-in, overexpression and library screening services for metabolic pathway research.
Conclusion
GO:0006526, L-arginine biosynthetic process, is a central metabolic pathway that supplies arginine for protein synthesis and for nitric oxide, polyamine and urea cycle metabolism. Its importance spans cancer immunometabolism, diabetes, cardiovascular disease and hypoxia-associated conditions. Understanding the genes and regulatory inputs of this process requires precise experimental models, and CRISPR-based knockout, point-mutation, knock-in and overexpression approaches provide the causal evidence needed to move from correlation to mechanism. Researchers can leverage these tools to dissect how L-arginine biosynthesis influences health and disease.
References
- 1. Geiger R et al.. 2016. L-Arginine Modulates T Cell Metabolism and Enhances Survival and Anti-tumor Activity.. Cell 167(3):829-842.e13 PMID: 27745970
- 2. Bao B et al.. 2024. Excessive Supplement of l-Arginine Induces Myopia via Orchestrating the MEK-ERK-NO Signaling Pathway.. J Agric Food Chem 72(47):26462-26474 PMID: 39535109
- 4. Thakur MR et al.. 2025. l-Arginine: A multifaceted regulator of diabetic cardiomyopathy.. Biochem Biophys Res Commun 761:151720 PMID: 40186920
- 5. Kurhaluk N. 2023. The Effectiveness of L-arginine in Clinical Conditions Associated with Hypoxia.. Int J Mol Sci 24(9) PMID: 37175912
- 6. Hu S et al.. 2017. L-Arginine Modulates Glucose and Lipid Metabolism in Obesity and Diabetes.. Curr Protein Pept Sci 18(6):599-608 PMID: 27356939
- 7. Szefel J et al.. 2019. Metabolic pathways of L-arginine and therapeutic consequences in tumors.. Adv Med Sci 64(1):104-110 PMID: 30605863
- 8. Hoang HH et al.. 2013. L-arginine, tetrahydrobiopterin, nitric oxide and diabetes.. Curr Opin Clin Nutr Metab Care 16(1):76-82 PMID: 23164986
